

HBsAg
Anti-HBs (GMT±SEM)
n = IgG2a/IgG1
10.45
9.76
6.17
0.16
None
24555
10103
7909
ODN
OVA
Anti-OVA (GMT ± SEM)
n=IgG2c/IgG1
20.9
83.5
7.92
0.03
0
None
24555
10103
7909
2137
ODN

Figure 1.



HBsAg
Anti-HBs (GMT±SEM)
ODN
None
24555
10103
7909
OVA
Anti-OVA (GMT ± SEM)
ODN:
None
24555
10103
7909
2137

Figure 2.



OVA
HBsAg
% Mean Specific Lysis (±SEM)
E:T Ratio
6.25:1
25:1
50:1
100:1
0
20
40
60
80
100
ODN
None
CPG 24555
CPG 10103
CPG 7909
Non-CpG 2137

Figure 3.



% Mean Specific Lysis (±SEM)
80
60
40
20
0
6.25:1
25:1
50:1
100:1
E:T Ratio
ODN
None
CPG 24555
CPG 10103
CPG 7909
Non-CpG 2137

Figure 4



% Tetramer +'ve CD8 T Cells
5
4
2
0
None
10103
24555
7909
2137
ODN
wild type mice
TLR9 deficient mice

Figure 5.



IFN-γ (pg/ml)
1000
800
600
400
200
0
0 (Media)
2.5
5.0
HBsAg (μg/ml)
IFN-γ (pg/ml)
4000
3000
2000
1000
0
0 (Media)
0.5
1.0
OVA (mg/ml)
None
CPG 10103
CPG 24555
CPG 7909
Non-CpG 2137

Figure 6.



2000
1500
1000
500
0
IFN-γ (pg/ml)
0 (Media)
0.5
1.0
OVA (mg/ml)
None
CPG 10103
CPG 24555
CPG 7909
Non-CpG 2137

Figure 7.



A: CD4 T Cells
Ag Alone
CPG 24555
CPG 10103
CPG 7909
B: CD8 T Cells
Ag Alone
CPG 24555
CPG 10103
CPG 7909
IFN-γ
TNF-α
IL-2
IFN-γ/IL-2
IFN-γ/TNF-α
TNF-α/IL-2
IFN-γ/IL-2/TNF-α

Figure 8.

ODN	IFN-α (6 donors)		MCP-1 (3 donors)		IP-10 (6 donors)	
	EC50 (nM)	Max (pg/mL)	EC50 (nM)	Max (pg/mL)	EC50 (nM)	Max (pg/mL)
CPG 10103	410	640	460	13,850	570	520
CpG 24555	310	800	390	17,990	220	490
Non-CpG ODN 22881	1,570	200	1,170	640	330	100

Figure 9A.

ODN	IL-6 (5 donors)		IL-10 (6 donors)		IL-2R (3 donors)	
	EC50 (nM)	Max (pg/mL)	EC50 (nM)	Max (pg/mL)	EC50 (nM)	Max (pg/mL)
CPG 10103	120	330	120	120	390	170
CpG 24555	190	450	100	160	190	200
Non-CpG ODN 22881	210	210	140	20	250	140

Figure 9B.

Figure 10A.




Figure 10B.





Figure 10C.






Figure 11A.




Figure 11B.




Figure 11C.




Figure 12A.




Figure 12B.




Figure 13A.




Figure 13B.



Anti-HA (GMT±SEM)
10000
8000
6000
4000
2000
0
Adjuvant
None
CPG 24555
CPG 10103
CPG 7909
Ctr. ODN 2137
Alum
24555/Alum
10103/Alum
7909/Alum
2137/Alum

Figure 14



HIA Titer
300
200
100
Naive
0
None
CPG 24555
CPG 10103
CPG 7909
Ctr ODN 2137
Alum
24555+Alum
10103+Alum
7909+Alum
2137+Alum

Figure 15



IFN-γ Concentration (pg/ml)
2000
1500
1000
500
0
Adjuvants:
None
CPG 24555
CPG 10103
CPG 7909
Crt. ODN 2137
Alum
CPG 24555+Alum
CPG 10103+Alum
CPG 7909+Alum
Ctr. ODN 2137+Alum

Figure 16



100000
10000
1000
100
10
1
Pre-P w0
Post-P w4
Post-B1 w6
Pre-B2 w8
Post-B2 w10
Engerix-B
Engerix-B + CPG 7909
Engerix-B+CPG24555

Figure 17



4 weeks post
1st boost
2 weeks post
2nd boost
Avidity Index (M)
2.5
2.0
1.5
1.0
0.5
0.0
Engerix-B
Engerix-B + CPG 7909
Engerix-B+CPG24555

Figure 18

Figure 19A




Figure 19B




Figure 19C




Figure 20 A




Figure 20 B




Figure 21A




Figure 21B

